trial

An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

NCTId NCT02320032
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 140 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2016-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
140 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2014-12
Primary completion
2016-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Alkermes Medical Director, MDStudy Director

Sites

16 total
Little Rock, United StatesCerritos, United StatesGarden Grove, United StatesWashington D.C., United StatesLauderhill, United StatesLeesburg, United StatesMaitland, United StatesOakland Park, United StatesTampa, United StatesAtlanta, United StatesChicago, United StatesHoffman Estates, United States

Facts & assertions

4 sourced
Enrollment
140
Phase
PHASE1
Primary Completion Date
2016-04
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Alkermes Medical Director, MD
person